StenoDK_img1_syddanmark

Steno Diabetes Center Odense

Special focus on people with type 2 diabetes

In autumn 2017, the Southern Denmark Regional Council and the Board of Directors of the Novo Nordisk Foundation approved the project plan for Steno Diabetes Center Odense

About Steno Diabetes Center Odense

The aim in creating Steno Diabetes Center Odense is to improve the prevention and the early detection of diabetes and to provide people with diabetes with patient-centred treatment of the highest international calibre so that they can optimally manage their diabetes and live a long life with as few complications as possible.

Steno Diabetes Center Odense will have four core activities: treating and preventing late complications; clinical research; developing the competencies of health professionals; and intersectoral collaboration. In addition, a special focus will be people with type 2 diabetes, including developing activities in such areas as prevention, detection, treating late complications, research, educating and training healthcare professionals, advising general practitioners and intersectoral collaboration.

“The Novo Nordisk Foundation’s ambition is that Denmark can offer the world’s best research-based treatment for diabetes.” Sten Scheibye, Chairman of the Board, Novo Nordisk Foundation

The Center, which will have the capacity to treat 9000 people with diabetes annually, will be located in a new building near the new Odense University Hospital.

Steno Diabetes Center Odense will play a major role in developing and improving the quality of the diabetes efforts throughout the Region of Southern Denmark. It will also become a regional driver in comprehensive clinical collaboration on treating and preventing diabetes, disseminating new knowledge and initiating new projects. This involves strong collaboration with the other hospitals in the Region and with general practitioners and the municipalities.

On 5 September 2017, the Foundation’s Board approved a grant of DKK 1.4 billion to the Region of Southern Denmark for establishing and operating Steno Diabetes Center Odense after the Regional Council approved a detailed plan for the Center on 28 August 2017.

“The Foundation’s ambition is that Denmark can offer the world’s best research-based treatment for diabetes. The establishment of the Center will strengthen the framework for improving patient-centred treatment and preventing late complications. The Center will also strengthen research, education and intersectoral collaboration. The goals are that the people who have diabetes can live longer with a better quality of life and that fewer Danes develop diabetes,” says Sten Scheibye, Chairman of the Board, Novo Nordisk Foundation.

The grant from the Foundation began in 2018 and will last until 2027, with a possible extension thereafter. The Foundation will fund the operating costs of the supplementary treatment of people with diabetes, clinical research, intersectoral collaboration and the development of competencies. In addition, the Foundation will also fund most of the construction and equipping of the new building.

Steno Diabetes Center Odense is operating from facilities at Odense University Hospital until the Center’s new building is ready for use, expected in 2022.

StenoDK_img1_syddanmark